Curcumin suppresses the production of interleukin-6 in *Prevotella intermedia* lipopolysaccharide-activated RAW 264.7 cells

Sung-Jo Kim*

Department of Periodontology, Pusan National University School of Dentistry, Yangsan, Korea

**Purpose:** Curcumin is known to exert numerous biological effects including anti-inflammatory activity. In this study, we investigated the effects of curcumin on the production of interleukin-6 (IL-6) by murine macrophage-like RAW 264.7 cells stimulated with lipopolysaccharide (LPS) from *Prevotella intermedia*, a major cause of inflammatory periodontal disease, and sought to determine the underlying mechanisms of action.

**Methods:** LPS was prepared from lyophilized *P. intermedia* ATCC 25611 cells by the standard hot phenol-water method. Culture supernatants were collected and assayed for IL-6. We used real-time polymerase chain reaction to detect IL-6 mRNA expression. IκB-α degradation, nuclear translocation of NF-κB subunits, and STAT1 phosphorylation were characterized via immunoblotting. DNA-binding of NF-κB was also analyzed.

**Results:** Curcumin strongly suppressed the production of IL-6 at both gene transcription and translation levels in *P. intermedia* LPS-activated RAW 264.7 cells. Curcumin did not inhibit the degradation of IκB-α induced by *P. intermedia* LPS. Curcumin blocked NF-κB signaling through the inhibition of nuclear translocation of NF-κB p50 subunit. Curcumin also attenuated DNA binding activity of p50 and p65 subunits and suppressed STAT1 phosphorylation.

**Conclusions:** Although further study is required to explore the detailed mechanism of action, curcumin may contribute to blockade of the host-destructive processes mediated by IL-6 and appears to have potential therapeutic values in the treatment of inflammatory periodontal disease.

**Keywords:** Curcumin, Periodontal disease, *Prevotella intermedia*, Lipopolysaccharides, Interleukin-6.

**INTRODUCTION**

Curcumin is a major phenolic compound found in the spice turmeric [1]. This compound has been shown to possess a wide spectrum of potential biological benefits, including antioxidant, anti-tumor, cardio-protective, antibacterial, antiviral, and anti-inflammatory properties [2-5]. Thus, curcumin has a potential therapeutic value against various chronic diseases, including allergies, rheumatoid arthritis, diabetes, cardiovascular diseases, cancer, and other chronic illnesses.

Periodontal disease is a chronic inflammatory process accompanied by destruction of surrounding connective tissue and alveolar bone, and sometimes loss of teeth [6]. The primary causative agents of periodontal disease are particular gram-negative anaerobic bacteria that accumulate in the gingival sulcus. *Prevotella intermedia* is a major periodontal pathogen that is dominant in the subgingival flora of patients with adult periodontitis [7,8], acute necrotizing ulcerative gingivitis [9], and pregnancy gingivitis [10].
Lipopolysaccharide (LPS) is a major component of the outer membrane of gram-negative bacteria, including *P. intermedia*. It can trigger a number of host cells to produce and release a wide variety of proinflammatory cytokines, including tumor necrosis factor alpha (TNF-α), IL-1β, IL-6, and IL-8 [11]. LPS preparations extracted from oral black-pigmented bacteria including *P. intermedia* have been reported to possess unique chemical and immunobiological properties quite different from those of the classical LPSs from the family *Enterobacteriaceae* such as *Escherichia coli* and *Salmonella* species [12-14].

Host responses to the specific causative bacteria and their metabolic products are a major determinant of disease pathogenesis. Recent work has demonstrated, in addition to bacterial control, that modulation of the host inflammatory response is a plausible therapeutic strategy for periodontal disease [15,16]. Therefore, host modulatory agents directed at inhibiting specific cytokines appear to be beneficial in terms of attenuating periodontal disease progression and potentially enhancing therapeutic responses. Therefore, in the present study we investigated the effects of curcumin on the production of IL-6 by macrophages stimulated with LPS from *P. intermedia* and sought to determine the underlying mechanisms of action.

**MATERIALS AND METHODS**

**Reagents**

Curcumin was obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against IκB-α, STAT1 and phospho-STAT1 were obtained from Cell Signaling Technology (Beverly, MA, USA), while antibodies against NF-κB p65, NF-κB p50, and PARP-1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

**Bacteria and culture conditions**

*P. intermedia* ATCC 25611 was used throughout. It was grown anaerobically on the surface of enriched Trypticase soy agar containing 5% (v/v) sheep blood, or in general anaerobic medium broth (Nissui, Tokyo, Japan) supplemented with 1 μg/mL menadione and 5 μg/mL hemin. Culture purity was assessed by gram staining and plating on solid medium.

**LPS isolation**

LPS was prepared from lyophilized *P. intermedia* ATCC 25611 cells by the standard hot phenol-water method as described previously [17]. The protein content of the purified LPS was less than 0.1%. Coomassie blue staining of overloaded sodium dodecyl sulfate (SDS)-polyacrylamide gels did not reveal any visible protein bands in the purified LPS, confirming the purity of the preparation (data not shown).

**Cell cultures**

The murine macrophage cell line RAW 264.7 (American Type Culture Collection, Rockville, MD, USA) was in Dulbecco’s modified Eagle’s medium as described previously [17]. The cells were seeded into 24-well culture plates at a density of 5×10⁶ cells/well and incubated for at least 12 hours to allow them to adhere to the plates. After washing three times with medium, various concentrations of *P. intermedia* LPS and curcumin were added and the cells were cultured for 24 hours, after which culture supernatants were collected and assayed for IL-6.

**Cytotoxicity assay**

The cellular toxicity of curcumin was assessed by the MTT assay. Cells were incubated with various concentrations of *P. intermedia* LPS and curcumin for 24 hours, and MTT was added to the cultures to a final concentration of 0.5 mg/mL. After incubation at 37°C in 5% CO₂ for 2 hours, the supernatant was removed and the cells were solubilized in dimethyl sulfoxide. The extent of reduction of MTT to formazan within the cells was quantified by measuring absorbance at 570 nm with a Spectra Max 250 ELISA Reader (Molecular Devices Inc., Sunnyvale, CA, USA).

**Measurement of IL-6 production**

The amount of IL-6 secreted into the culture medium was determined by enzyme-linked immunosorbent assay (ELISA) using a commercially available kit (OptEIA, BD Biosciences Pharmingen, San Diego, CA, USA) according to protocols recommended by the manufacturer.

**RNA extraction and real-time polymerase chain reaction (PCR) for IL-6 mRNA**

Cells were plated in 100 mm tissue culture dishes at a density of 1×10⁶ cells/dish and treated with various concentrations of *P. intermedia* LPS and curcumin for 24 hours. Total RNA was isolated with an RNasy Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. cDNA was prepared from 1 μg of the total RNA using iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). A real-time PCR was performed using the CFX96 real-time PCR detection system (Bio-Rad Laboratories Inc.) with a specific primer for mouse IL-6. As an endogenous control, β-actin primer was used. PCR was conducted with SsoFast EvaGreen Supermix (Bio-Rad Laboratories Inc.) according to the manufacturer’s instruction. Thermal cycler conditions were as follows: After denaturing at 98°C for 10 seconds, PCR was performed for 45 cycles, each of which consisted of denaturing at
95°C for 1 second, annealing/extending at 60°C for 5 seconds.

The following PCR primers for IL-6 (162 bp), and β-actin (149 bp) were used: IL-6 sense, 5′-GCCAGAGTCTCTAGAGAGAGA-
TACAG-3′ and antisense, 5′-GAATTGATGCTTTGTCCT-
CTTAGC-3′; β-actin sense, 5′-TGAGAGGAAATCGTGCAGT-
GAC-3′ and antisense, 5′-GATCGTGCAATAGTGA-TAG-
GACC-3′. Each assay was normalized to β-actin mRNA.

**Immunoblotting analysis**

Cells were plated in 60-mm tissue culture dishes, at a den-
sity of 4×10⁵ cells per dish, and treated with various concen-
trations of *P. intermedia* LPS and curcumin for the indicated
periods of time. Cell lysates were prepared as described pre-
viously [17]. The nuclear fraction was prepared from cells us-
ing the ActiveMotif nuclear extract kit (Active Motif, Carlsbad,
CA, USA) according to the manufacturer’s instructions. Pro-
tein concentrations were determined with the bicinchoninic
acid protein assay reagents (Pierce, Rockford, IL, USA) ac-

**DNA-binding activity of NF-κB**

Cells were plated in 60-mm tissue culture dishes, at a den-
sity of 4×10⁵ cells per dish, and incubated with curcumin (20
μM) in the absence or presence of *P. intermedia* LPS (10 μg/
ml) for the indicated periods of time. After extracting the
nuclear protein as described above, the DNA-binding activity
of NF-κB in nuclear extract was assayed by using a TransAM
NF-κB p65/NF-κB p50 transcription factor assay kits (Active
Motif) according to the manufacturer’s recommended pro-
cedure. Oligonucleotide with the NF-κB consensus binding
site (5′-GGGACTTTCC-3′), to which the activated NF-κB
contained in nuclear extracts specifically binds, has been im-
mobilized on a 96-strip well plate. The activated NF-κB p65
and p50 specifically bound to this oligonucleotide was de-
tected using specific antibodies to NF-κB p65 and p50, re-
spectively. A Spectra Max 350 ELISA Reader was used to read
the sample absorbance, with results expressed as optical den-
sity emitted at 450 nm.

**Statistical analysis**

Data are expressed as means±SD and statistical analysis
was performed using Student’s t-test with *P<0.05* consid-
ered statistically significant.

**RESULTS**

**Effects of curcumin on *P. intermedia* LPS-induced IL-6 pro-
duction**

Stimulation of RAW 264.7 cells with *P. intermedia* LPS in-
duced significant increases in IL-6 (Fig. 1). Curcumin inhib-
ited IL-6 production dose-dependently in *P. intermedia* LPS-
treated cells. Treatment of cells with 20 μM curcumin re-
duced IL-6 production by 83%. Curcumin did not affect the
cell viability as determined by MTT assay (data not shown),
indicating that inhibitory effects of curcumin on IL-6 pro-
duction was unrelated to its cytotoxicity. As shown in Fig. 2,
curcumin also reduced *P. intermedia* LPS-induced IL-6 mRNA
expression in a dose-dependent manner.

**Effects of curcumin on *P. intermedia* LPS-induced NF-κB
activation**

The previous study [17] showed that the NF-κB and JAK2/
STAT1 pathways are involved in IL-6 production induced by
*P. intermedia* LPS. First, the effect of curcumin on *P. interme-
dia* LPS-induced degradation of IκB-α, upstream signaling
pathway of NF-κB, was determined by immunoblotting. The
degradation of IκB-α induced by LPS was not inhibited when
cells were co-treated with curcumin (Fig. 3). Next, the effects
of curcumin on the nuclear translocation of NF-κB subunits
were examined. Nuclear fractions were immunblotted with

![Figure 1. Effects of curcumin on *Prevotella intermedia* lipopolysac-
charide (LPS)-induced production of interleukin (IL)-6 in RAW 264.7
cells. Cells were incubated with different doses of curcumin (0, 1, 5,
10, and 20 μM) in the absence or presence of *P. intermedia* LPS (10
μg/mL). Supernatants were removed after 24 hours and assayed for
IL-6. The results are means±standard deviation of three indepen-
dent experiments. *P<0.01 versus *P. intermedia* LPS alone.](image-url)
Curcumin suppresses *P. intermedia* LPS-induced IL-6 production

**Figure 2.** Effects of curcumin on *Prevotella intermedia* lipopolysaccharide (LPS)-induced interleukin (IL)-6 mRNA expression in RAW 264.7 cells. Cells were incubated with different doses of curcumin (0, 1, 5, 10, and 20 μM) in the absence or presence of *P. intermedia* LPS (10 μg/mL) for 24 hours. Real-time polymerase chain reaction was performed with EvaGreen Supermix, β-actin being used as an endogenous control. Data are presented as percentage of *P. intermedia* LPS alone. The results are means ± standard deviation of three independent experiments. *a*P < 0.05, *b*P < 0.01 vs. *P. intermedia* LPS alone.

Curcumin did not affect *P. intermedia* LPS-induced p65 nuclear translocation. Instead, translocation of p50 subunit was dose-dependently hampered in the presence of curcumin (Fig. 4A). Finally, DNA-binding activity of NF-κB in nuclear extract was analyzed by using the ELISA-based NF-κB p65/κB p50 transcription factor assay kits. DNA-binding activities of NF-κB p65 and p50 subunits induced by *P. intermedia* LPS were attenuated by treatment with curcumin (Fig. 4B).

**Effects of curcumin on *P. intermedia* LPS-induced phosphorylation of STAT1**

It was examined whether curcumin regulates *P. intermedia* LPS-induced IL-6 production through inhibiting the STAT1 pathway. STAT1 phosphorylation induced by *P. intermedia* LPS was dose-dependently inhibited by curcumin (Fig. 5).

**DISCUSSION**

It is well known that LPSs from periodontal pathogens induce excess production of inflammatory mediators, such as NO, TNF-α, and IL-6 in immune cells [17-20]. These proinflammatory mediators are potential targets for the development of new therapeutic approaches to the treatment of periodontitis, because these molecules play a significant role in the development of periodontal destruction.

The results of the present study indicate that curcumin suppresses the production of IL-6 at both gene transcription and translation levels in *P. intermedia* LPS-activated RAW 264.7 cells. IL-6 is important in the pathogenesis of periodontal disease. Clinically, IL-6 levels in sites with periodontal disease are higher than those in healthy sites and closely related to the severity of periodontal disease [21,22]. Moreover, it has been well demonstrated that IL-6 is a potent bone resorptive agent, induces osteoclastogenesis, and hence plays important roles in alveolar bone resorption in periodontal disease [23,24]. Blockade of IL-6, therefore, could be a highly efficient tool for blocking the development and progression of inflammatory periodontal disease.

It is generally accepted that multiple signal transduction pathways participate in LPS-induced activation of macrophages and resultant production of proinflammatory cytokines, and NF-κB pathways play critical roles. NF-κB is a transcription factor that plays a critical role in the expressions of proinflammatory cytokines and other mediators [25-28]. In this study, curcumin did not inhibit NF-κB transcriptional activity at the level of IκB-α degradation. Curcumin blocked NF-κB signaling through inhibition of nuclear translocation of NF-κB p50 subunit induced with *P. intermedia* LPS. In addition, curcumin also attenuated DNA-binding activities of NF-κB p65 and p50 subunits. P50 usually forms a heterodimer with other NF-κB subunits and participates in target gene transcription [29,30]. Inhibition of NF-κB activity by curcumin would be useful in the treatment of inflammatory periodontal disease.

The STAT signaling pathway plays an essential role in the regulation of inflammatory responses [31]. The seven STAT family members are identified in mammals, and each one binds to a different DNA sequence [32]. The STAT family of transcription factors are activated by JAKs [33,34]. STAT1, downstream of JAK2, appears to be an important transcription factor for LPS-induced gene expressions in macrophages [35]. In this study, curcumin down-regulated *P. intermedia* LPS-induced IL-6 production via regulating the STAT1 pathway. Thus, the STAT1 signaling pathway could be a potential mo-
molecular target for treating periodontal disease.

In summary, this study shows that curcumin strongly suppresses IL-6 production induced by LPS from *P. intermedia* in macrophages. The underlying mechanisms of curcumin involve the inhibition of NF-κB and STAT1 pathways. Although further study is required to explore the detailed mechanism of action, curcumin may contribute to blockade of the host-destructive processes mediated by IL-6 and appears to have potential therapeutic values in the treatment of inflammatory periodontal disease.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGEMENT**

This work was supported for two years by Pusan National University Research Grant.
REFERENCES